{"id":"aripiprazole-titrated-dose","safety":{"commonSideEffects":[{"rate":"10-25%","effect":"Akathisia"},{"rate":"10-20%","effect":"Headache"},{"rate":"5-15%","effect":"Anxiety"},{"rate":"5-15%","effect":"Insomnia"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Weight gain"},{"rate":"5-10%","effect":"Tremor"},{"rate":"5-10%","effect":"Sedation"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Aripiprazole acts as a partial agonist at dopamine D2 receptors, meaning it can both activate and inhibit dopamine signaling depending on baseline dopamine levels, providing a stabilizing effect on dopaminergic neurotransmission. It also has partial agonist activity at 5-HT1A receptors and antagonist activity at 5-HT2A receptors, contributing to its antipsychotic and mood-stabilizing effects. This unique pharmacological profile distinguishes it from typical antipsychotics and may result in a favorable side effect profile.","oneSentence":"Aripiprazole is a partial agonist at dopamine D2 and serotonin 5-HT1A receptors that modulates dopaminergic and serotonergic neurotransmission in the brain.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:02:25.070Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Schizophrenia"},{"name":"Bipolar I disorder (acute manic or mixed episodes)"},{"name":"Major depressive disorder (adjunctive treatment)"},{"name":"Autism spectrum disorder (irritability)"}]},"trialDetails":[{"nctId":"NCT06937476","phase":"NA","title":"Neurobiological Mechanisms of Pathological Rumination and Effects of Aripiprazole","status":"RECRUITING","sponsor":"Central South University","startDate":"2025-05-08","conditions":"Major Depressive Disorder (MDD), Rumination","enrollment":108},{"nctId":"NCT06049953","phase":"","title":"Maternal And Infant Antipsychotic Study","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2023-09-29","conditions":"Antipsychotics, Pregnancy","enrollment":200},{"nctId":"NCT06969755","phase":"PHASE4","title":"Biomarkers to Enhance Early Schizophrenia Treatment","status":"NOT_YET_RECRUITING","sponsor":"Northwell Health","startDate":"2025-07-30","conditions":"Schizophenia Disorder","enrollment":180},{"nctId":"NCT03198078","phase":"PHASE3","title":"Trial to Evaluate the Short-term Safety & Efficacy of Brexpiprazole Monotherapy in the Treatment of Adolescents With Schizophrenia","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2017-06-30","conditions":"Schizophrenia","enrollment":316},{"nctId":"NCT01354353","phase":"PHASE1","title":"A Study of Safety and Tolerability in Subjects With Schizophrenia","status":"COMPLETED","sponsor":"Denovo Biopharma LLC","startDate":"2011-05","conditions":"Schizophrenia","enrollment":75},{"nctId":"NCT01123707","phase":"PHASE3","title":"To Assess the Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)","status":"TERMINATED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2010-11-18","conditions":"Major Depressive Disorder (MDD)","enrollment":173},{"nctId":"NCT01111565","phase":"PHASE3","title":"Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)","status":"TERMINATED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2010-10-04","conditions":"Major Depressive Disorder (MDD)","enrollment":137},{"nctId":"NCT01111552","phase":"PHASE3","title":"Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)","status":"TERMINATED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2010-07-29","conditions":"Major Depressive Disorder (MDD)","enrollment":237},{"nctId":"NCT01111539","phase":"PHASE3","title":"Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)","status":"TERMINATED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2010-07-13","conditions":"Major Depressive Disorder (MDD)","enrollment":211},{"nctId":"NCT01416441","phase":"PHASE3","title":"Safety and Tolerability Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2011-10-19","conditions":"Tourette's Disorder","enrollment":170},{"nctId":"NCT03661983","phase":"PHASE4","title":"Trial to Evaluate the Long-term Efficacy of Oral Aripiprazole in the Treatment of Pediatric Participants With Tourette's Disorder","status":"TERMINATED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2018-10-13","conditions":"Tourette's Disorder (TD)","enrollment":36},{"nctId":"NCT03289026","phase":"PHASE4","title":"Pharmacologic Treatment of Acute Episode of Schizophrenia: a Real World Study","status":"COMPLETED","sponsor":"Peking University","startDate":"2017-09-01","conditions":"Acute Schizophrenia Episode","enrollment":770},{"nctId":"NCT00712270","phase":"PHASE4","title":"Best Event Schizophrenia Trial--A Randomized Double-Blind Trial of Aripiprazole and Risperidone in Schizophrenia","status":"TERMINATED","sponsor":"Kettering Health Network","startDate":"2005-04","conditions":"Schizophrenia","enrollment":21},{"nctId":"NCT01231074","phase":"PHASE1","title":"Reducing Antipsychotic-Induced Weight Gain in Children With Metformin","status":"COMPLETED","sponsor":"Nationwide Children's Hospital","startDate":"2010-02","conditions":"Obesity, Weight Gain, Psychotropic Induced Weight Gain","enrollment":96},{"nctId":"NCT02529163","phase":"NA","title":"Evaluating the Efficacy of a Late-Life Schizophrenia Integrated Care Pathway to Treat Acute Psychotic Symptoms","status":"UNKNOWN","sponsor":"Centre for Addiction and Mental Health","startDate":"2015-08","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":24},{"nctId":"NCT00509067","phase":"PHASE2","title":"Use of Galantamine and CDP-choline (Citicoline) to Treat Adults With Schizophrenia","status":"COMPLETED","sponsor":"Georgetown University","startDate":"2007-11","conditions":"Schizophrenia","enrollment":43},{"nctId":"NCT00665444","phase":"NA","title":"Study of Aripiprazole to Reduce Medical Risks in Bipolar Disorder","status":"TERMINATED","sponsor":"University of Pittsburgh","startDate":"2008-04","conditions":"Bipolar Disorder, Metabolic Syndrome","enrollment":3},{"nctId":"NCT00241176","phase":"PHASE4","title":"Open Label Trial of Aripiprazole in Children and Adolescents With Tourette's Disorder","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2005-09","conditions":"Tourette's Syndrome, Tic Disorders","enrollment":11},{"nctId":"NCT00466310","phase":"PHASE1","title":"Metabolic Signatures and Biomarkers in Schizophrenia","status":"COMPLETED","sponsor":"Duke University","startDate":"2007-02","conditions":"Schizophrenia","enrollment":71},{"nctId":"NCT00216476","phase":"PHASE3","title":"A Study of Relapse Prevention and the Effectiveness of Long-acting Injectable Risperidone and Quetiapine Tablets in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder","status":"COMPLETED","sponsor":"Janssen-Cilag International NV","startDate":"2004-10","conditions":"Schizophrenia, Psychotic Disorders","enrollment":753},{"nctId":"NCT00876343","phase":"PHASE3","title":"Study of Aripiprazole as an Adjunctive Therapy in Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2009-03","conditions":"Major Depressive Disorder","enrollment":586},{"nctId":"NCT00665366","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Aripiprazole Administered With Lithium or Valproate Over 12 Weeks in the Treatment of Mania in Bipolar I Disorder","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2008-06","conditions":"Bipolar Disorder Mania","enrollment":493},{"nctId":"NCT00102063","phase":"PHASE3","title":"Aripiprazole in Adolescents With Schizophrenia","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2004-07","conditions":"Schizophrenia","enrollment":302},{"nctId":"NCT00347425","phase":"PHASE3","title":"Switch Study of Existing Atypical Antipsychotics to Bifeprunox","status":"COMPLETED","sponsor":"Solvay Pharmaceuticals","startDate":"2006-12","conditions":"Schizophrenia and Schizoaffective Disorder","enrollment":286}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Aripiprazole"],"phase":"phase_3","status":"active","brandName":"Aripiprazole (Titrated dose)","genericName":"Aripiprazole (Titrated dose)","companyName":"Otsuka Pharmaceutical Co., Ltd.","companyId":"otsuka","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Aripiprazole is a small molecule partial agonist of the dopamine D2 receptor, classified as a partial agonist. It is used to treat conditions such as Major Depressive Disorder, Schizophrenia, and Schizoaffective Disorder, among others, and is typically titrated to an effective dose.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}